Profile of infantile malignancies at tertiary cancer center—A study from south India

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 20026-20026 ◽  
Author(s):  
M. HS ◽  
B. Aruna Kumari ◽  
L. Appaji ◽  
S. V. Attili ◽  
D. Padma ◽  
...  
Keyword(s):  
Hematological Malignancies ◽  
Tertiary Care ◽  
Germ Cell Tumors ◽  
Cancer Center ◽  
South Indian Population ◽  
Pediatric Malignancies ◽  
Wilm's Tumor ◽  
Solid Malignancies ◽  
Common Diagnosis ◽  
Wilm’S Tumor

20026 Background: Infantile malignancies are peculiar in the way they present with lot of diversity and had poor prognosis compared to other pediatric malignancies. The spectrum of malignancies had a great regional variability owing to the environmental and genetic differences (both aquired, maternal and paternal). Methods: It is a retrospective data analysis conducted at a tertiary care cancer center, Bangalore, India. The institute has an annual attendance of 16,000 new cases with reasonably good follow-up. The contribution of pediatric malignancies is 18%. The details were collected from the case records and percentages were calculated for the variables. Results: Between 2003–2006 we diagnosed 1,798 pediatric tumors. Of them 198 (11%) are infantile malignancies. The commonest diagnosis at our center is leukemia (30% of all infantile malignancies). The main types of leukemia are ALL-80%, AML-13%, and CML-7%. Other hematological malignancies are lymphomas- 2%, myelo proliferative disorders and Langerhan Cell histiocytosis-3% each. The next common diagnosis is benign neoplasms, wrongly diagnosed as malignant at the secondary referral center which contributed 16% of all cases. The reminder 46% is solid malignancies. In the decreasing frequency the incidences are Wilm’s tumor-12%, neuroblastoma-10%, germ cell tumors-8%, retinoblastoma- 6% CNS malignancies and 3% hepatoblastoma -2%. The reminders are other rare malignancies. Conclusion: The contribution of infantile malignancies at our center is relatively higher compared to the west. Similarly Relative contribution of AML to the all hematological malignancies and neurblastoma & CNS tumors to solid malignancies is less compared to the existing literature. Wilm’s tumor and ALL diagnosed more frequently than expected in our population. All these findings together suggest that south Indian population had a different spectrum of infantile malignancies compared to rest of the world and their genetic and environmental risk factors need further exploration. No significant financial relationships to disclose.

Wilm’s Tumor: Syndrome-Based and Molecular Diagnostics

2017 ◽  
Vol 4 (4) ◽  
pp. 283-289 ◽  
Author(s):  
S. A. Kulyova ◽  
E. N. Imyanitov
Keyword(s):  
Molecular Diagnostics ◽  
Wilm's Tumor ◽  
Wilm’S Tumor

397 Intra-tumor immunotherapy injections utilizing image guidance in interventional radiology: clinical trial experience at a tertiary care cancer center

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A422-A422
Author(s):  
Ravi Murthy ◽  
Rahul Sheth ◽  
Alda Tam ◽  
Sanjay Gupta ◽  
Vivek Subbiah ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Interventional Radiology ◽  
Real Time ◽  
Image Guidance ◽  
Tertiary Care ◽  
Cancer Center ◽  
Imaging Guidance ◽  
Image Guided ◽  
Real Time Image ◽  
Time Image

BackgroundImage guided intra-tumor administration of investigational immunotherapeutic agents represents an expanding field of interest. We present a retrospective review of the safety, feasibility & technical nuances of real-time image guidance for injection & biopsy across a spectrum of extracranial solid malignancies utilizing the discipline of Interventional Radiology.MethodsPatients who were enrolled in image guided intratumoral immunotherapy injection (ITITI) clinical trials over a 6 year period (2013–19) at a single tertiary care cancer center were included in this analysis. Malignancy, location, imaging guidance utilized for ITITI & biopsy for injected (adscopal) & non-injected (abscopal) lesions were determined and categorized. Peri-procedural adverse events were noted.Results262 pts (146 female, 61 yrs median) participating in 29 immunotherapeutic clinical trials (TLR & STING agonists, gene therapy, anti CD-40, viral/bacterial/metabolic oncolytics) met study criteria. Malignancies included melanoma 88, sarcoma 32, colorectal 29, breast 23, lung 17, head & neck 15, ovarian 8, neuroendocrine 7, pancreatic adenocarcinoma 6, 3 each (cholangioCA, endometrial, bladder, GI tract), 2 each (RCC, thymicCA, lymphoma, merkel cell, prostate) & others 1 each (CUP, GIST, dermatofibrosarcoma, DSRT, neuroblastoma, thyroid). All 169 & 93 patients received the intended 1371 ITITI in parietal (abdominal/chest wall, extremity, neck, pelvis) or visceral (liver, lung, peritoneum, adrenal) locations respectively; 83 patients received lymph node injections within either location. Imaging guidance was US in 68% of the cohort (US 161, CT+US 19); CT was used in 30% (81) & MRI in 1 patient. Median diameter of the ITITI lesion was 32 mm (8–230 mm). Median volume of the ITITI therapeutic material/session was 2 ml (1–6.9 ml). Lesions were accessed using a coaxial technique. ITITI delivery needles used at operator preference & tailored to lesion characteristics were either a 21G/22G Chiba, 21G Profusion (Cook Medical), 22G Morrison (AprioMed), 25G hypodermic (BD) & 18G Quadrafuse (Rex Medical). 2840 core biopsies (>18G Tru-cut core, Mission, Bard Medical) were performed in 237 patients during 690 procedures; biopsy sessions were often concurrent & of the ITITI site. 137 patients also underwent biopsy of a non-ITITI site (89 parietal location). Dimensions of the non-ITITI lesion were median 10 mm (7–113 mm); US image guidance was used in 97 patients (72%) to obtain a total of 1257, >18G Tru-core samples. 1.3% of injections resulted in SAE (NCI CTC AE >3) and 0.5% of 4097 biopsies developed major complications (SIR Criteria); both categories were manageable.ConclusionsUtilizing real time image guidance, ITITI to the administration of a myriad of investigational immunotherapeutic agents with concomitant biopsy procedures to date are associated with a high technical success rate & favorable safety profile.AcknowledgementsJoshua Hein, Mara Castaneda, Jyotsna Pera, Yunfang Jiang,Shuang Liu, Holly Liu and Anna LuiTrial RegistrationN/AEthics ApprovalThe study was approved by Institution’s Ethics Board, approval number 2020-0536: A retrospective study to determine the safety, feasibility and technical challenges of real-time image guidance for intra-tumor injection and biopsy across multiple solid tumors.Consent2020-0536 Waiver of Informed ConsentReferenceSheth RA, Murthy R, Hong DS, et al. Assessment of image-guided intratumoral delivery of immunotherapeutics in patients with cancer. JAMA Netw Open 2020;3(7):e207911. doi:10.1001/jamanetworkopen.2020.7911

scholarly journals Maintaining an Adult Hematology/Oncology Service at a Tertiary Care Center during the SARS-CoV-2 Pandemic: An Eight-Week-Experience with a Newly Implemented Procedural Plan

2021 ◽  
pp. 1-6
Author(s):  
Philipp G. Hemmati ◽  
Dorothea Fischer ◽  
Frank Breywisch ◽  
Sabine Wohlfarth ◽  
Matthias Kramer ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Care Center ◽  
Tertiary Care ◽  
Cancer Center ◽  
Staff Members ◽  
Oncology Service ◽  
Containment Measures ◽  
Vulnerable Patient ◽  
Set Up ◽  
Oncology Unit

Treatment of cancer patients has become challenging when large parts of hospital services need to be shut down as a consequence of a local COVID-19 outbreak that requires rapid containment measures, in conjunction with the shifting of priorities to vital services. Reports providing conceptual frameworks and first experiences on how to maintain a clinical hematology/oncology service during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are scarce. Here, we report our first 8 weeks of experience after implementing a procedural plan at a hematology/oncology unit with its associated cancer center at a large academic teaching hospital in Germany. By strictly separating team workflows and implementing vigorous testing for SARS-CoV-2 infections for all patients and staff members irrespective of clinical symptoms, we were successful in maintaining a comprehensive hematology/oncology service to allow for the continuation of treatment for our patients. Notably, this was achieved without introducing or further transmitting SARS-CoV-2 infections within the unit and the entire center. Although challenging, our approach appears safe and feasible and may help others to set up or optimize their procedures for cancer treatment or for other exceedingly vulnerable patient cohorts.

scholarly journals Enhanced Cleaning and Education to Prevent Transmission of Clostridium difficile in Pediatrics

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S406-S406
Author(s):  
Anoshé Aslam ◽  
Giselle Melendez ◽  
Min Wang ◽  
Frederic Stell ◽  
Paulette Kelly ◽  
...  
Keyword(s):  
Clostridium Difficile ◽  
Tertiary Care ◽  
Educational Interventions ◽  
Cancer Center ◽  
Phase 2 ◽  
Communication Plan ◽  
Effective Strategies ◽  
Key Stakeholders ◽  
Patient Representatives ◽  
Healthcare Associated

Abstract Background Transmission of healthcare-associated Clostridium difficile infection (HA-CDI) has been shown to occur directly or indirectly through a contaminated environment. At a tertiary-care cancer center, HA-CDI rates were higher for pediatric units than for other general oncology units. To address the problem, a multidisciplinary team, including Infection Control, Nursing, and Environmental Services (EVS), was convened and identified refusals and room clutter as barriers to proper cleaning of rooms on the unit. Aim: The aim of this study seeks to reduce HA-CDI in the inpatient pediatrics setting through environmental and educational interventions. Methods In the first phase of the study from February to April 2016, a baseline assessment of prevalent environmental disinfection practices was made among Nursing, EVS, Physicians, and Patient Representatives. Based on this feedback, the following were implemented during Phase 2, from June through October 2016: 1) Unit-wide disinfection with bleach twice a day including common and high traffic areas; 2) Initiation of a “preferred time for cleaning” program to engage families; 3) Enhanced visitor and family education on PPE use; 4) Creation of a communication plan in case of refusal to clean rooms; and 5) Dedicated use of diaper scales. Results During the first phase of the study, the following barriers to cleaning were identified: 1) High refusal rate as cleaning was perceived as inconvenient by families due to timing; 2) Common perception among EVS staff that multiple requests for cleaning the room may appear intrusive to the families; 3) Excessive clutter in the room; 4) Lack of education regarding PPE use; and 5) Shared equipment for diapers. To overcome these barriers, several interventions as outlined in methods were implemented. In Phase 2, there were 0 cases of HA-CDI identified in pediatric patients starting in July through October, 2016. Conclusion Control of CDI on pediatric units poses unique challenges. Engagement of key stakeholders is essential to identify and meet these challenges and to devise effective strategies that will ultimately lead to reduced hospital-based transmission of CDI. Disclosures All authors: No reported disclosures.

scholarly journals GCT-30. TREATMENT OF PRIMARY INTRACRANIAL GERM CELL TUMORS: SINGLE INSTITUTION EXPERIENCE OF 74 CASES WITHOUT HISTOLOGICAL CONFIRMATION

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii334-iii334
Author(s):  
Chengcheng Guo ◽  
Qunying Yang ◽  
Jian Wang ◽  
Yonggao Mou ◽  
Zhongping Chen
Keyword(s):  
Germ Cell ◽  
Tumor Therapy ◽  
Survival Rates ◽  
Gamma Knife Radiosurgery ◽  
Germ Cell Tumors ◽  
Cancer Center ◽  
Chemotherapy Group ◽  
Tumor Group ◽  
Intracranial Germ Cell Tumors ◽  
Histological Confirmation

Abstract BACKGROUND AND OBJECTIVE Primary intracranial germ cell tumors (PIGCTs) are a group of heterogeneous tumors. It is very difficult to treat those patients without pathological diagnosis. This study retrospectively analyzed the clinical data and outcomes of patients with clinically diagnosed (without histologically confirmed) PIGCTs in SunYat-sen University Cancer Center. METHODS Patients who were clinically diagnosed as PIGCTs without histological diagnosis through surgical resection or biopsy were included in this study. Patients were analyzed for clinical characteristics, treatment patterns, outcomes and adverse effects. RESULTS From May 2002 to July 2014, 74 patients clinically diagnosed with PIGCTs received chemotherapy and/or radiotherapy at the Sun Yat-sen University Cancer Center. The median age was 16.5 years old (4–45 years old, majority was teenagers). The most of tumors were found in male, and located in the pineal and suprasellar regions. When the patients were grouped into diagnostic chemotherapy group (57 cases), diagnostic radiotherapy group (5 cases) and gamma knife radiosurgery group (12 cases) based on their initial anti-tumor therapy. The 5-year survival rates were 84.3%, 75.0% and 75.0%, respectively. There was a trend that the chemotherapy group got a better survival. Patients were allocated to secretory tumor group (49 cases) and non-secretory tumor group (25 cases) based on their levels of tumor makers (α-FP and β-hCG). The 5- year survival rates were 80% and 77.8% (P value = 0.966), respectively. CONCLUSION Clinical diagnosed PIGCT (without histological confirmation) patients may obtain good responses when receiving comprehensive treatments of chemotherapy combined with radiotherapy.

ID: 3526546 CLINICAL OUTCOMES OF GASTRIC AND DUODENAL NEUROENDOCRINE TUMORS. EXPERIENCE FROM A LARGE TERTIARY CARE CANCER CENTER

2021 ◽  
Vol 93 (6) ◽  
pp. AB13-AB14
Author(s):  
Martin Coronel ◽  
Abraham Yu ◽  
Shria Kumar ◽  
Phillip S. Ge ◽  
Graciela M. Nogueras-González ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Neuroendocrine Tumors ◽  
Tertiary Care ◽  
Cancer Center ◽  
Large Tertiary Care ◽  
Duodenal Neuroendocrine Tumors

scholarly journals CAR T cell therapy in solid tumors: a short review

2021 ◽  
Author(s):  
Öykü Umut ◽  
Adrian Gottschlich ◽  
Stefan Endres ◽  
Sebastian Kobold
Keyword(s):  
T Cell ◽  
Cell Therapy ◽  
Solid Tumors ◽  
Hematological Malignancies ◽  
Short Review ◽  
T Cell Therapy ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Solid Malignancies ◽  
Car T

SummaryChimeric antigen receptor (CAR) T cell therapy has been established in the treatment of hematological malignancies. However, in solid tumors its efficacy remains limited. The aim of this article is to give an overview of the field of cell therapy itself, to introduce the underlying concepts of CAR T cell-based treatment approaches and to address its limitations in advancing the treatment for solid malignancies.

Sign in / Sign up

Export Citation Format

Share Document